Traditional and disease-related non-computed variables affect algorithms for cardiovascular risk estimation in

Giacomo Cafaro1, Carlo Perricone1, Ilenia Riccucci1

  • 1Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Italy.

Insights

Cardiovascular risk prediction in rheumatoid arthritis and Sjögren's syndrome patients is suboptimal with current algorithms. Disease activity and inflammatory markers are crucial for accurate risk assessment in these populations.

Area of Science:

  • Rheumatology
  • Cardiovascular Medicine
  • Epidemiology

Background:

  • Cardiovascular (CV) risk algorithms often underestimate risk in rheumatic diseases due to exclusion of disease-specific factors.
  • Rheumatoid arthritis (RA) and Sjögren's syndrome (SS) patients have unique pathophysiological pathways contributing to CV disease.
  • Accurate CV risk stratification is essential for managing these patient populations.

Purpose of the Study:

  • To evaluate the performance of two established CV risk algorithms (Reynolds Risk Score and "Progetto Cuore") in RA and SS cohorts.
  • To identify specific variables not included in these algorithms that significantly predict CV risk in RA and SS patients.
  • To inform the development of more accurate CV risk assessment tools for individuals with rheumatic conditions.

Main Methods:

  • A cohort of 77 RA patients and 68 SS patients without prior CV events was analyzed.
  • Clinical, serological, and traditional CV risk factors were collected for all participants.
  • Ten-year CV risk was calculated using the Reynolds Risk Score (RSS) and "Progetto Cuore" algorithms.

Main Results:

  • The prevalence of traditional CV risk factors and predicted 10-year CV risk were comparable between RA and SS cohorts.
  • In RA, body mass index (BMI) and disease activity predicted "Progetto Cuore" risk, while BMI and bone erosions predicted RSS.
  • In SS, C-reactive protein predicted "Progetto Cuore" risk, whereas hypertension, ESSDAI, and LDL-cholesterol predicted RSS.

Conclusions:

  • The 10-year risk for fatal and non-fatal CV events is similar in RA and SS patients.
  • Traditional CV risk factors, such as hypertension, significantly influence CV risk in these rheumatic disease cohorts.
  • Inflammatory parameters and disease activity are critical disease-specific variables that warrant inclusion in future CV risk assessment algorithms for rheumatic diseases.
Abstract

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
120
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
94
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
56
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
86
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
64
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.7K